Technostics Limited, Hull, UK.
Drug Dev Ind Pharm. 2010 May;36(5):614-23. doi: 10.3109/03639040903388290.
Alginate-based gastroesophageal reflux disease treatments have been used extensively and fall into two main categories. Those containing alginate as the principle active agent and those containing alginate in combination with a significant amount of antacid.
The effectiveness of the raft formed by a new alginate/antacid suspension (Gaviscon Double Action Liquid, GDAL), in which calcium carbonate was the main antacid ingredient, was compared with those of existing alginate/antacid suspensions.
GDAL had similar raft strength and improved raft resilience than Gaviscon Liquid (GL), and both were significantly greater than five other products tested. Gastric retention of GDAL was similar to that of GL.
the in vitro and in vivo performance is maintained in the new GDAL formulation even with higher antacid levels and the product is as good as, or better than, previous formulations.
基于藻酸盐的胃食管反流病治疗已被广泛应用，并分为两类。一类主要活性成分为藻酸盐，另一类则含有大量抗酸剂与藻酸盐的混合物。
比较了一种新型藻酸盐/抗酸悬浮液（Gaviscon Double Action Liquid，GDAL）——其中碳酸钙为主要抗酸成分——形成的浮筏与现有藻酸盐/抗酸悬浮液的效果。
GDAL 的浮筏强度和浮筏弹性与 Gaviscon Liquid（GL）相似，均明显大于另外五种测试产品。GDAL 在胃内的滞留时间与 GL 相似。
即使抗酸剂水平较高，新的 GDAL 配方在体外和体内的性能仍保持不变，且产品与之前的配方一样好，甚至更好。
